[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinica Universidad de Navarra, Universidad de Navarra\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":655},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,56,85,108,131,152,181,211,234,260,275,307,324,354,380,409,445,478,504,529,550,572,596,615,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100625550","phase-2-intratumoral-dnx-2401-for-high-grade-pediatric-brain-tumors-100625550",false,"NCT07424092","Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors","Intratumoral DNX-2401 Administration for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients","PED-DNX2401","Inclusion Criteria:\n\n* The participant or participant's parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and the pediatric participant provides writ-ten assent, where applicable, based on age and country requirements.\n* Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors \\[medulloblastomas, ATRT, EMTR, pineoblastoma\\], and ependymomas) diagnosis based on initial histopathological diagnosis and further clinical and radiological fol-low-up, in whom gross total resection is not feasible, and with a life expectancy of at least 16 weeks at the time of consent.\n* Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at least 12 weeks after completion of ra-diation therapy, or if there is clear histopathological confirmation of tumor recurrence.\n* Male and female participants age ≥ 1 years and ≤ 25 years.\n* A single measurable lesion longer than 10 mm in two perpendicular diameters, considered by the investigator to be accessible for safe stereotactic biopsy and virus injection.\n* Lansky Performance Status (LPS) ≥ 60 for participants \\\u003C 16 years, or Karnofsky Performance Status (KPS) ≥ 60 for participants ≥ 16 years.\n* No other chemotherapy or immunotherapy in the 4 weeks before inclusion.\n* Steroids: free off or requiring decreasing or stable corticosteroid dose (≥ 0.05 mg\u002Fkg dexa-methasone daily, or equivalent for other steroids) in the 2 weeks before DNX-2401 admin-istration.\n* Radiation: no craniospinal irradiation, total body irradiation nor focal irradiation in the 6 weeks before inclusion.\n* Autologous Stem Cell Transplantation: patients must be ≥ 3 months post-transplant prior to entry of the study.\n* Patients must be fully recovered from all acute treatment related toxicities of all prior therapies.\n* Laboratory test: adequate hematological (platelets ≥ 100x10e9\u002FL, neutrophils ≥ 1.0x10e9\u002FL, hemoglobin ≥ 5,6 mmol\u002FL), renal function (creatinine \\\u003C1.5 times ULN) and liver function (≤3 times ULN) values.\n* Negative pregnancy test for female participants of child-bearing potential, where child-bearing potential is defined as a fertile female who is pubertal or post-pubertal and not permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy).\n* Female participants of child-bearing potential, who are sexually active, agree to use ac-ceptable birth control starting at informed consent and continuing for at least 120 days af-ter DNX-2401 administration. Male participants agree to use acceptable birth control start-ing at informed consent and continuing for at least 90 days after DNX-2401 administration.\n\nExclusion Criteria:\n\n* Any medical or psychological condition or disease that might interfere with the subject's ability to participate or give informed consent (if older than 16 years).\n* Spinal location, or lesions considered risky for stereotactic injection of virus or that might favor entrance of the virus in the ventricular system.\n* Any treatment outside the allowable guidelines outlined in the inclusion criteria.\n* Severe acute infection or intercurrent medical condition including, but not limited to se-vere renal, hepatic, heart or bone marrow failure that based on investigator discretion do not permit inclusion in the study.\n* Subjects with immunodeficiency or autoimmune conditions, active hepatitis or known HIV. No testing for Hepatitis B, Hepatitis C and HIV is required unless mandated by local health authority.\n* Subjects with another primary malignancy.\n* Prior history of encephalitis, multiple sclerosis or other CNS infections or primary CNS dis-ease that would interfere with evaluation.\n* Li Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its relat-ed pathways.\n* Concurrent therapy with any antiviral drug or any immunosuppressive drug (except ster-oids).\n* Life or life-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted.\n* Prior participant in experimental viral therapy.\n* Inability to undergo MRI scans for any reason.\n* Pregnancy or breastfeeding.","ALL","1 Year","25 Years",{"count":22,"type":23},39,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401.\n\nThe main questions it aims to answer are:\n\n* Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival?\n* Is a single intratumoral administration of DNX-2401 safe and well tolerated?\n\nParticipants will:\n\n* Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401\n* Visit the clinic periodically for checkups and tests",[29,30,31,32,33,34,35],"High Grade Glioma","Ependymoma","Embryonal Tumor of Brain","Recurrence","Refractory","Pediatric","Young Adult",[37,29,30,38,39,40,41,42],"High Grade Brain Tumors","Embryonal CNS Tumors","Recurrent or refractory","Pediatric and young adult patients","Oncolytic virus","DNX-2401","RECRUITING","2026-05-21",{"date":46,"type":47},"2026-05-27","ACTUAL",{"date":49,"type":47},"2026-05-12",{"date":51,"type":23},"2029-05",{"name":53,"class":54},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",2,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":18,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":24,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100624906","artichoke-by-products-rich-in-hydroxycinnamic-acids-and-mediterranean-diet-for-type-2-diabetes-prevention-100624906","NCT07415720","Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.","Multiomic Evaluation of the Effect of Artichoke By-products Supplementation Rich in Hydroxycinnamic Acids, Integrated Into an Energy-restricted Mediterranean Diet, on the Prevention of Type 2 Diabetes.","ARTI-UP","Inclusion Criteria:\n\n* BMI between 25.0 and 35.0 kg\u002Fm²\n* HOMA-IR ≥ 2.5.\n* Adequate physical examination and vital signs or clinically irrelevant to the intervention (those not related to metabolic health).\n* Subjects must be able to understand and be willing to sign the informed consent form, and must comply with all study procedures and requirements.\n* Subjects must have a stable means of communication, either by email and\u002For telephone.\n\nExclusion Criteria:\n\n* Weight loss of more than 5% in the last 6 months prior to surgery.\n* Consumption of antibiotics in the 3 months prior to the intervention.\n* Subjects who are undergoing treatment for weight loss\u002Fbody composition modification, use medication for weight loss or blood glucose control, or have had weight loss surgery.\n* Have a medical diagnosis of type 1 or type 2 diabetes.\n* History of inflammatory bowel disease and\u002For resection of the large or small intestine. Subjects with relevant functional or structural abnormalities of the digestive system.\n* Inability to follow the recommended diet or physical exercise.\n* Unavailability in terms of time or location to attend study visits.\n* Failure to sign the informed consent form.\n* Inability to communicate with the research team.\n* Endocrine-related excess weight (except for treated hypothyroidism, at least 3 months of stable treatment).\n* Being pregnant or planning a pregnancy during the intervention period.\n* Being breastfeeding.\n* Having an allergy to artichokes.\n* Severe psychiatric illnesses that have required hospitalisation in the last 6 months.\n* Renal failure.\n* Having immunodeficiency or being HIV positive.\n* Being treated with immunosuppressive drugs or cytotoxic agents.\n* High alcohol intake: more than 14 units (women) and 20 units (men) per week.\n* Participation in another randomised clinical trial.\n* Volunteers undergoing drug treatment for less than 3 months with a stable dose\u002Fstable treatment.\n* Taking nutritional supplements (supplements: plant derivatives, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for 3 months prior to the start of the trial.\n* Taking nutritional supplements (supplements: plant-derived, for weight loss, fibre and probiotics) unless the person is willing to stop taking them for the 16 weeks of the study intervention and a minimum washout period of 14 days prior to baseline measurements is guaranteed.\n* Having donated blood in the 14 days prior to the baseline visit.\n* Subjects with any type of cancer or undergoing treatment for cancer, or who have not been in remission for at least 5 years.\n* Any other condition that may interfere with adherence to the intervention.",true,"18 Years","75 Years",{"count":68,"type":23},150,[70],"NA","The ARTI-UP study evaluates whether daily consumption of a supplement made from artichoke by-products, rich in hydroxycinnamic acids (HCAs), in combination with an energy-restricted Mediterranean diet (erMeDiet), can improve glycaemic control, reduce insulin resistance and contribute to weight loss in subjects with overweight or obesity. In addition, it seeks to understand the biological mechanisms involved using omic techniques and to establish predictive biomarkers that will enable progress towards personalised nutrition strategies.",[73,74,75],"Diabete Type 2","Obesity & Overweight","Insulin Resistance Syndrome","2026-04-28",{"date":78,"type":47},"2026-04-29",{"date":80,"type":23},"2026-05",{"date":82,"type":23},"2027-12",{"name":53,"class":54},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":55},"100567273","gastric-pocus-for-airway-management-in-patients-using-glucagon-like-peptide-1-receptor-agonist-multicentric-100567273","NCT06666049","Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)","POCUS","Inclusion Criteria:\n\nAdults patients ,ASA I-III, taking GLP-1 analog medications, undergoing scheduled surgery.\n\nExclusion Criteria:\n\n1. \\- History of esophagogastric pathology or previous abdominal surgery.\n2. \\- Hiatal hernia\u002Fgastroesophageal reflux disease.\n3. \\- Autonomic nervous system disorders.\n4. \\- Neurological or neuromuscular diseases.\n5. \\- Use of medications\u002Fdrugs that affect autonomic regulation and delay gastric emptying (opioids) or potentiate it (prokinetics).\n6. \\- Pregnancy.\n7. \\- Presence of arrhythmias.","90 Years",{"count":22,"type":23},"OBSERVATIONAL","1\\. Introduction\n\nScheduled surgery requires patients to undergo a preoperative fasting period of at least 6 hours to reduce the risk of perioperative pulmonary aspiration. However, certain medications and conditions may delay gastric emptying, potentially increasing aspiration risk. These include diabetic gastroparesis and the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity.\n\nGLP-1 receptor agonists are widely used due to their beneficial effects on glycemic control and weight reduction. However, one of their known effects is delayed gastric emptying, which may result in increased residual gastric content despite adherence to standard fasting guidelines. Recent reports have described cases of pulmonary aspiration during anesthesia in patients receiving GLP-1 receptor agonists, even after appropriate fasting.\n\nGiven the increasing use of these medications, there is a need for objective assessment tools to evaluate gastric content in the perioperative setting. Gastric ultrasonography has emerged as a non-invasive bedside technique that may help identify patients at increased risk of aspiration and guide airway management strategies.",[97],"Aspiration Pneumonia",[99,100],"Bronchopulmonary complications","Ultrasound",{"date":102,"type":47},"2026-05-05",{"date":104,"type":47},"2024-10-21",{"date":106,"type":23},"2026-12-01",{"name":53,"class":54},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":92,"enrollmentInfo":114,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":84},"100583842","airway-coach-project-prediction-of-videolaryngoscopy-strategy-with-clinical-and-ultrasound-parameters-multicentric-100583842","NCT06881589","Airway Coach Project: Prediction of Videolaryngoscopy Strategy With Clinical and Ultrasound Parameters (Multicentric)","Inclusion Criteria:\n\n* Patients (male or female) ASA I-III, aged between 18 and 90 years, undergoing scheduled surgery requiring orotracheal intubation. The signature of the informed consent is required authorizing its inclusion in the study.\n\nExclusion Criteria:\n\n* Obesity class II defined as a BMI greater than 35.\n* Pregnant.\n* Cervical tumors, goiter or patients who have required radiotherapy at the cervical level\n* Abnormalities that condition anatomy alterations such as facial \u002F cervical fractures.\n* Maxillofacial abnormalities\n* People who cannot give their consent",{"count":115,"type":23},210,"This multicentre observational study will collect clinical parameters, demographic data, and point-of-care airway ultrasound measurements from adult patients undergoing videolaryngoscopy across participating centres. The collected data will be analysed using artificial intelligence-based analytical approaches, including statistical and machine-learning techniques, to examine their association with predefined videolaryngoscopy-related outcomes.",[118],"Difficult Videolaryngoscopy",[120,121,122],"Ultrasound;","AI analyses","Difficult Videolaryngoscopy,","2026-04-09",{"date":125,"type":47},"2026-04-15",{"date":127,"type":47},"2025-01-27",{"date":129,"type":23},"2026-09-01",{"name":53,"class":54},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":64,"sex":18,"minAge":65,"maxAge":92,"enrollmentInfo":138,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":84},"100514835","pocus-assessment-for-tracheal-vs-oesophageal-intubation-100514835","NCT05983666","POCUS ASSESSMENT FOR TRACHEAL VS OESOPHAGEAL INTUBATION","PATO","Inclusion Criteria:\n\nPatients (male or female) ASA I-III, aged between 18 and 90 years, undergoing scheduled and\u002For emergency surgery requiring orotracheal intubation. Informed consent form must be signed authorising inclusion in the study.\n\nExclusion Criteria:\n\nA.- Cervical tumours, goitre or patients who have required cervical radiotherapy.\n\nB.- Abnormalities leading to alterations of the anatomy such as facial\u002Fcervical fractures.\n\nC.- Those who cannot give their consent.",{"count":139,"type":23},200,"The clinical importance of airway management has gained prominence in the last decade in most scientific societies with the aim of improving the standard of care.\n\nThe WHO has focused guidelines for \"Safety in Surgery\", which attempt to encompass all methods that predict and recognise airway management risk and should be applied by the surgical team, and has therefore created and implemented a surgical checklist that can be useful in reducing the risk of unidentified difficulties.\n\nThe same suggestion has been included in the Helsinki Declaration on Patient Safety in Anaesthesiology, signed by most European entities in cooperation with the European Society of Anaesthesiology (ESA), the European Board of Anaesthesiology (EBA-UEMS), and the World Federation of Societies of Anaesthesiology (WFA).\n\nConfirmation of correct endotracheal tube (ET) placement is a crucial step in airway management, as unrecognised oesophageal intubation can have catastrophic consequences. Numerous methods are used to verify correct ET placement, including visual confirmation of tube passage through the vocal cords during laryngoscopy, chest wall expansion during ventilation, visualisation of the tracheal rings and carina using a flexible bronchoscope, auscultation, capnometry, capnography and chest radiography. These techniques vary in their degree of precision. Although capnography is considered the gold standard for confirming tracheal intubation, it has some important limitations.\n\nIn recent years, ultrasonography has been introduced as the fifth pillar of the physical examination of the patient: inspection, palpation, percussion, auscultation and insonation. For airway assessment and management, Point-of-Care UltraSound (PoCUS) has been incorporated into routine clinical practice, answering open diagnostic questions, aiding in differential diagnosis and guiding procedures.\n\nThus, investigators propose a simple, quick and easy-to-learn approach for the interpretation of ultrasound imaging findings during airway management.",[142],"Intubation Complication",[144,100],"Tracheal intubation",{"date":146,"type":47},"2026-04-14",{"date":148,"type":47},"2023-07-01",{"date":150,"type":23},"2026-08-01",{"name":53,"class":54},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":64,"sex":160,"minAge":4,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":55},"100627346","role-of-pro-resolving-lipid-mediators-in-obesity-associated-diseases-100627346","NCT07447440","Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases","Unraveling the Role of Pro-Resolving Lipid Mediators of Inflammation and Their Receptors in Obesity-Associated Diseases: New Therapeutic Approaches for Maresin 1 (RESOLBE)","RESOLBE","HEALTHY PARTICIPANTS:\n\nInclusion Criteria:\n\n* Postmenopause (al least 1 year).\n* Normoweight or overweight\u002Fobesity.\n* No personal history of cancer.\n* Stable weight over the last 3 months (±5%).\n* Willing to sign the informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Personal history of cancer.\n* Current weight loss treatment (diet, supplementation, surgery, others...).\n* Bariatric surgery.\n* No stable pharmacological treatment for at least 3 months.\n* Diabetes treatment and hormone replacement therapy.\n* Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.\n* High alcohol intake, more than 14 units per week for women and 20 units per week for men.\n* Surgical interventions resulting in permanent sequelae of the gastrointestinal tract.\n* Liver disease, except for non-alcoholic fatty liver disease.\n* Cognitive and\u002For psychiatric impairment.\n* Poor compliance or difficulty following study procedures.\n\nBREAST CANCER PARTICIPANTS:\n\nInclusion Criteria:\n\n* Postmenopause (at least 1 year).\n* Normoweight or overweight\u002Fobesity.\n* Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment.\n* Willing to sign the informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Luminal subtype breast cancer stages over than II or other type of breast cancer.\n* Require preoperative treatment.","FEMALE",{"count":162,"type":23},60,"The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight\u002Fobesity.\n\nSpecific objectives are:\n\n* To analyse anthropometric and body composition changes.\n* To evaluate physical activity level.\n* To determine dietary profile.\n* To determine the adherence to Mediterranean dietary pattern.\n* To assess the quality of life.\n* To determine levels of specialized pro-resolving lipid mediators\n\nThe target sample size is 60 subjects. Participants will be allocated in four groups:\n\n* Group 1: Postmenopausal healthy women with overweight\u002Fobesity (n=15)\n* Group 2: Postmenopausal healthy women with normoweight (n=15)\n* Group 3: Postmenopausal women with breast cancer and overweight\u002Fobesity (n=15)\n* Group 4: Postmenopausal women with breast cancer and normoweight (n=15)",[165,166,167],"Breast Cancer","Health, Subjective","Obesity",[169,170,171,172,167],"Breast","Cancer","Postmenopause","Lipid mediators","2026-03-09",{"date":175,"type":47},"2026-03-11",{"date":177,"type":47},"2025-10-15",{"date":179,"type":23},"2027-12-30",{"name":53,"class":54},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":64,"sex":18,"minAge":65,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":192,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":84},"100605662","effect-of-a-postbiotic-supplementation-in-overweight-and-obese-subjects-a-randomized-controlled-trial-parabiotics-2-100605662","NCT07165431","Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2).","Clinical Evaluation of a Postbiotic Supplement in Overweight and Obese Subjects: A Randomized Controlled Trial.","PARABIOTICS-2","Inclusion Criteria:\n\n* Male and female participants aged 18 to 70 years.\n* Volunteers with overweight or obesity (BMI: ≥ 27-39.9 kg\u002Fm²) and a body fat percentage of ≥ 30% for women and ≥ 20% for men.\n* Stable body weight (±5%) for at least the three months prior to study initiation.\n* Normal physical examination and vital signs, or clinically non-relevant findings for the purposes of the study (i.e., not related to metabolic health).\n* Subjects must be able to understand and willing to sign the informed consent form, and comply with all study procedures and requirements.\n* Continued pharmacological\u002Fhormonal treatment will be permitted provided it does not affect the study parameters and that the dosage has remained stable at least the previous three months to the start of the intervention. Treatment with insulin or any drug with a hypoglycemic effect will be excluded\n* Willingness to undergo all study procedures (including the daily consumption of a 1 g gummy during the intervention).\n* Time and geographic availability to attend the two on-site clinical evaluation sessions at the scheduled times (including a 3-hour session during visit 2).\n\nExclusion Criteria:\n\n* Volunteers undergoing pharmacological treatment will be excluded if the treatment has not been stable for at least 3 months prior to study initiation. Excluded treatments include:\n* Those that alter gastrointestinal function.\n* Chronic use of stomach protectors.\n* Any hypoglycemic drugs or insulin.\n* Subjects with significant functional or structural abnormalities of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.\n* Subjects who have undergone surgical interventions resulting in permanent sequelae in the digestive tract (e.g., gastroduodenostomy) or bariatric surgery.\n* Subjects with chronic metabolic diseases or obesity-related conditions, or systemic intestinal, hepatic, or renal diseases, including type 1 or 2 diabetes, severe dyslipidemia, uncontrolled thyroid disorders, cirrhosis, inflammatory bowel disease, untreated anemia, etc. (Non-alcoholic fatty liver disease will not be an exclusion criterion).\n* Exceeding the alcohol consumption limit established for each sex (more than 14 units per week for women and 20 units per week for men).\n* Pregnant or breastfeeding women, or those planning to become pregnant.\n* Use of nutritional supplements (such as weight loss supplements, newly initiated fiber supplements, probiotics, postbiotics, etc.) containing compounds that may affect study outcomes, unless the participant agrees to discontinue them during the 12-week intervention period and a minimum 15-day washout period prior to baseline measurements is ensured.\n* Blood donation within 14 days prior to the baseline visit.\n* Subjects with any type of cancer or undergoing cancer treatment, or for whom less than 5 years have passed since remission.\n* Subjects allergic to any component of the study product or to any other food that could interfere with or hinder study compliance.\n* Subjects presenting any type of cognitive and\u002For psychiatric impairment.\n* Subjects anticipated to have poor compliance or who, in the investigator's opinion, may have difficulty adhering to study procedures.\n* Subjects currently undergoing treatment for weight loss or body composition modification.\n* Subjects who are taking or have taken antibiotics within 60 days prior to the baseline visit.","70 Years",{"count":191,"type":23},114,[70],"The principal objective of this project is to evaluate the effect of a postbiotic supplement (inactivated microorganism) on body composition and other physiological and metabolic parameters related to excess body weight in overweight or obese adult men and women, as well as to determine changes in the gut microbiota associated with these outcomes.\n\nSpecific objectives are focus on evaluate the effect of the intervention on the following parameters:\n\n* Changes in body weight and composition.\n* Changes in glucose tolerance.\n* Changes in gut microbiota (metagenomics).\n* Changes in urinary and serum metabolites.\n* Changes in routine biochemical variables related to carbohydrate and lipid metabolism, as well as liver parameters.\n* Changes in specific markers involved in obesity pathology, such as insulin, leptin, adiponectin, and cytokines MCP-1, TNF, CRP, and others.\n* Adherence to the nutritional recommendations and the gummy containing postbiotic formula.\n* Changes in the level of physical activity.\n\nTarget sample size is 114 subjects, including a 10% of drop out.\n\nParticipants will be allocated in two groups for 12 weeks:\n\n* Experimental group (n=57): nutritional recommendations + postbiotic supplement\u002Fgummy.\n* Placebo group (n=57): nutritional recommendations + placebo supplement\u002Fgummy.\n\nParticipants will visit the nutritional intervention unit at weeks 1 and 12. A follow-up phone call will be conducted at week 6.",[195,196,197],"Nutrition, Healthy","Weight Loss","Overweight and Obesity",[199,167,200,201,202],"Postbiotic","Nutritional advice","Microbiota","Glucose tolerance","2026-02-16",{"date":205,"type":47},"2026-02-19",{"date":207,"type":47},"2025-12-01",{"date":209,"type":23},"2026-06-30",{"name":53,"class":54},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":219,"targetDuration":19,"studyType":94,"phases":4,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100621434","no-axillary-surgery-in-early-breast-cancer-oxigenate-100621434","NCT07370571","NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE)","NO AXILLARY SURGERY IN EARLY BREAST CANCER","OXIGENATE","Inclusion Criteria:\n\nOlder than 18 years old cT1-2 cN0 Negative preoperative assessment of the axilla Breast surgery as first treatment No axillary surgery Multifocal\u002F multicentric breast cancer Candidates to receive breast conserving surgery Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.\n\nPatients must be accessible for follow-up.\n\nExclusion Criteria Synchronous distant metastases Any axillary surgery Neoadjuvant treatment Previous malignancy Bilateral breast cancer Previous primary systemic therapy Pregnancy or breastfeeding Pre-operative diagnosis (cytology or histology) of axillary lymph node metastases Pre-operative radiological evidence of multiple involved or suspicious nodes Patients with psychiatric, addictive, or any disorder, which compromises their ability to give informed consent for participation in this study.",{"count":220,"type":23},827,"Prospective study will establish a comprehensive international registry specifically for patients who have undergone surgery for primary breast cancer without SLNB. The main objective of this registry is to gather detailed, real-world data on the outcomes of this particular treatment approach, providing insights into the clinical efficacy and quality of life of patients when SLNB is omitted.",[165],[224],"omission SLN, breast cancer","NOT_YET_RECRUITING","2026-01-17",{"date":228,"type":47},"2026-01-27",{"date":230,"type":23},"2026-03-01",{"date":232,"type":23},"2032-03-30",{"name":53,"class":54},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":64,"sex":18,"minAge":242,"maxAge":65,"enrollmentInfo":243,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":55},"100583841","video-classification-of-intubation-in-spain-vci-pediatrics-100583841","NCT06881576","Video Classification of Intubation in Spain (VCI) (Pediatrics)","Video Classification of Intubation in Spain (Pediatrics)","VCI","Inclusion Criteria:\n\n* Pediatric Patients who decide to undergo scheduled surgery at our hospital during a period of 1 year (2025).","0 Years",{"count":244,"type":23},1500,"Use of VCI in Spain",[247],"Difficult Intubation",[249,250,251,252],"Difficult intubation","Airway","Videolaryngoscopy","Score","2026-01-05",{"date":255,"type":47},"2026-01-06",{"date":257,"type":47},"2025-03-12",{"date":106,"type":23},{"name":53,"class":54},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":240,"eligibilityCriteria":266,"healthyVolunteers":64,"sex":18,"minAge":65,"maxAge":92,"enrollmentInfo":267,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":245,"conditions":268,"keywords":269,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":55},"100557393","video-classification-of-intubation-in-spain-vci-100557393","NCT06537531","Video Classification of Intubation in Spain (VCI)","Video Classification of Intubation in Spain","Inclusion Criteria:\n\n* Patients from any geographical area of the Iberian Peninsula who decide to undergo scheduled surgery at our hospital during a period of 6 months (2024-25).\n\nExclusion Criteria:\n\n* Age \\\u003C18",{"count":244,"type":23},[247],[249,250,251,252],{"date":255,"type":47},{"date":272,"type":47},"2024-07-26",{"date":106,"type":23},{"name":53,"class":54},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":283,"targetDuration":19,"studyType":94,"phases":4,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},"100609274","monitoring-coughs-for-the-early-detection-of-worsening-copd-100609274","NCT07212439","Monitoring Coughs for the Early Detection of Worsening COPD","Continuous Cough Monitoring for Early Detection of COPD Exacerbations Using Hyfe","Hyfe-EPOC","Inclusion criteria:\n\n* Must be 18 years of age or older.\n* Must have an existing diagnosis of COPD.\n* For the inpatient cohort, participants must be currently assessed as having a moderate\u002Fsevere exacerbation.\n* For the outpatient cohort, participants must have had at least one exacerbation of any severity in the last 12 months.\n* For the outpatient cohort, at least one month must have passed since the last exacerbation.\n\nExclusion criteria:\n\n* Individuals who are unable to provide informed consent.\n* Individuals who are unable to adhere to study procedures.\n* For the inpatient cohort, individuals requiring invasive or non-invasive ventilation.\n* Individuals who live with a person who has a chronic cough.",{"count":284,"type":23},50,"This study is for adults with COPD. Flare-ups of COPD, also known as exacerbations, can be serious and lead to hospital stays. The purpose of this research is to see if continuously and automatically monitoring a person's coughs can help predict these flare-ups early, before they become severe. Participants will use the Hyfe cough monitoring system, which includes a watch-like device worn on the wrist and a smartphone application. The system privately counts the number of coughs without recording any audio. Participants will also answer a short, weekly questionnaire about their COPD symptoms. This is an observational study, which means it will not change the regular medical care a participant receives. The participants and their care providers will not see the cough counts. The doctor will continue to manage their COPD as usual.",[287],"Chronic Obstructive Pulmonary Disease (COPD)",[289,290,291,292,293,294,295,296,297],"COPD","COPD Exacerbation","Cough","Cough Monitoring","Hyfe","Early Detection","Wearable Device","Artificial Intelligence","Observational Study","2025-12-30",{"date":300,"type":47},"2026-01-02",{"date":302,"type":47},"2025-10-29",{"date":304,"type":23},"2026-09",{"name":53,"class":54},3,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":92,"enrollmentInfo":312,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":84},"100587178","airway-coach-project-prediction-of-videolaryngoscopy-strategy-with-clinical-and-ultrasound-parameters-unicentric-100587178","NCT06925009","Airway Coach Project: Prediction of Videolaryngoscopy Strategy With Clinical and Ultrasound Parameters (Unicentric)",{"count":313,"type":23},280,"This unicentric observational study collects clinical characteristics, demographic data, and point-of-care airway ultrasound measurements in patients undergoing videolaryngoscopy. These variables are analysed using machine-learning techniques to examine their association with predefined videolaryngoscopy-related outcomes, including blade performance and adjunct requirement.",[118],[317],"Ultrasound;Difficult Videolaryngoscopy; Machine Learning",{"date":300,"type":47},{"date":320,"type":47},"2023-01-27",{"date":322,"type":23},"2026-06-01",{"name":53,"class":54},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":84},"100614784","nutritional-intervention-with-tenebrio-molitor-powder-in-children-with-chronic-malnutrition-in-the-democratic-republic-of-the-congo-100614784","NCT07284095","Nutritional Intervention With Tenebrio Molitor Powder in Children With Chronic Malnutrition in the Democratic Republic of the Congo","SANTE INITIATIVE: Nutritional Intervention With Tenebrio Molitor Powder in Children With Chronic Malnutrition in the Democratic Republic of the Congo","SANTE","Inclusion Criteria:\n\n* Children diagnosed with chronic malnutrition (weight-for-height or BMI below -2 SD according to WHO standards).\n\nChildren whose families agree to participate in the intervention and sign the informed consent form.\n\nExclusion Criteria:\n\n* Children with severe acute illnesses that may interfere with the intervention.\n* Children with known allergies to the ingredients of the nutritional products provided.","2 Years","10 Years",{"count":335,"type":23},40,[70],"The goal of this clinical trial is to evaluate whether a dietary supplement based on Tenebrio molitor (mealworm flour) can improve nutritional status and biomarkers of micronutrient deficiency in children aged 2-10 years.\n\nThe main questions it aims to answer are:\n\n• Does regular supplementation with Tenebrio molitor flour improve chronic malnutrition status\n\nResearchers will compare the intervention group (children receiving Tenebrio molitor flour supplement) with the control group (children receiving a traditional maize-soy flour supplement) to assess differences in biochemical and anthropometric outcomes after the intervention period.\n\nParticipants will:\n\n* Participate in baseline and follow-up anthropometric and blood sample assessments (hemoglobin, albumin, zinc, iron, calcium, magnesium, vitamin A, folic acid, vitamin B12, prealbumin).\n* Consume a daily dietary supplement (either Tenebrio molitor flour or maize-soy flour) for the duration of the intervention.\n* Provide information on dietary intake and general health status through structured questionnaires administered by the research team.",[339,340],"Chronic Malnutrition","Stunting of Growth",[339,342,343,344,345],"Stunting","Tenebrio Molitor","Food Security","Sustainable Foods","2025-12-15",{"date":348,"type":47},"2025-12-16",{"date":350,"type":23},"2026-02-01",{"date":352,"type":23},"2026-08",{"name":53,"class":54},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":362,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":379},"100614798","phase-1-ttfields-and-chemotherapy-in-metastatic-pancreatic-adenocarcinoma-mpdac-100614798","NCT07284277","TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","Phase Ib-II, Non-randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With modFOLFIRINOX for Front-line Treatment of Metastatic Pancreatic Adenocarcinoma (NOVOFFOX)","Inclusion Criteria:\n\nAll the patients should comply with the following criteria for inclusion:\n\n1. Histological\u002Fcytological diagnosis of pancreatic adenocarcinoma.\n2. The patient should be 18 years of age and older.\n3. The patient has given consent to participate in the study.\n4. The patient should be able to comply with all the requirements of the clinical trial.\n5. Life expectancy of at least 3 months.\n6. Metastatic disease with, at least, one hepatic lesion that must be accessible for biopsy.\n7. Measurable disease as defined by Response Evaluation Criteria in Solid Tumor v1.1 (RECIST 1.1) apart from the liver lesion to be biopsied.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n9. Amenable and assigned by the investigator to receive therapy with modFOLFIRINOX.\n10. Prior chemotherapy or radiotherapy on the neoadjuvant or adjuvant setting is allowed as long as at least six months have elapsed since last chemotherapy treatment.\n11. Able to operate the Novo TTF-200T System independently or with the help of a caregiver.\n12. Adequate hematologic and organ function, defined by the following laboratory test results, obtained during the screening period and before C1D1.\n\n    1. WBC higher than or equal to 2.5 x 10\\^9\u002FL.\n    2. ANC higher than or equal to 1.5 x 10\\^9\u002FL without granulocyte colony-stimulating factor support.\n    3. Platelet count higher than or equal to 100 x 10\\^9\u002FL without transfusion.\n    4. Hemoglobin higher than or equal to 9 g\u002FdL. Patients may be transfused to meet this criterion.\n    5. Albumin higher than or equal to 2.5 g\u002FdL.\n    6. Serum bilirubin lower than or equal to 1.5 times the upper limit of normal (ULN); patients with known Gilbert´s disease may have a bilirubin value lower than or equal to 3 x ULN.\n    7. INR and aPTT lower than or equal to 1.5 x ULN.\n    8. AST, ALT, lower than or equal to 5 x ULN.\n    9. Serum creatinine lower than or equal to 1.5 x ULN or Creatinine Clearance higher than or equal to 30ml\u002Fmin (calculated using Cockcroft-Gault formula).\n13. For women of childbearing potential: Negative serum pregnancy test within 14 days prior to C1D1. Agreement to remain abstinent (refrain from heterosexual intercourse) or use of contraceptive methods that result in a failure rate of lower than or equal to 1 percentage per year during the treatment period (combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal o transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable o implantable); intrauterine device (IUD) or intrauterine hormone-releasing system (IUS); bilateral tubal occlusion or vasectomized partner) and for at least 180 days after the last study treatment. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (higher than or equal to 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus).\n\nExclusion Criteria:\n\nPatients who present any of the following criteria for exclusion cannot be included in the clinical trial:\n\n1. Malignancies other than pancreatic cancer within 3 years prior to Cycle 1 Day 1 (C1D1) with the exceptions of those with a negligible risk of metastasis or death (e.g., expected 5-year overall survival higher than 90 percentage), treated with expected curative outcome (such as but not limited to: adequately treated in situ carcinoma of the cervix, basal squamous or melanomatous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ of the breast treated surgically with curative intent).\n2. Previous treatment with chemotherapy for metastatic pancreatic ductal adenocarcinoma.\n3. Untreated CNS metastases. Treatment of brain metastases, either by surgical or radiation techniques, must have been completed at least 4 weeks prior to study entry.\n4. Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthase gene polymorphism predisposing the patient for 5-fluorouracil (5-FU) toxicity.\n5. Previous radiation therapy within 14 days prior to C1D1 and\u002For persistence of radiation-related adverse effects.\n6. Implantable electronic medical devices in the torso, such as pacemakers.\n7. Known severe hypersensitivities to medical adhesives or hydrogel, or history of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study treatments used.\n8. Spinal cord compression not definitively treated with surgery and\u002For radiation.\n9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n10. Pregnant and lactating women\n11. Patients who have received brivudine, sorivudine or analogues 4 weeks prior to Fluoracile administration.\n12. Serious co-morbidities, including but not limited to:\n\n    1. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second\u002Fthird degree hart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse.\n    2. History of cerebrovascular accident (CVA) within 3 months prior to randomization or that is not stable.\n    3. Active infection or serious underlying medical condition that would impair the ability of the patient to receive protocol therapy.\n    4. History of any psychiatric condition that might impair patient´s ability to understand or comply with the requirements of the study or to provide consent.",{"count":5,"type":23},[363,26],"PHASE1","The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields).\n\nThe main questions it aims to answer are:\n\n* Is TTFields treatment safe for the patients in combination with modFOLFIRINOX?\n* Are participants compliant with the treatment?\n* Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?",[366,367],"Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma",[369,370,371],"Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma","Pancreatic Adenocarcinoma","2025-12-02",{"date":348,"type":47},{"date":375,"type":47},"2025-10-14",{"date":377,"type":23},"2027-03",{"name":53,"class":54},5,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":64,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100607642","co-designed-comprehensive-transition-programme-for-first-line-nurse-managers-100607642","NCT07191210","Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers","A Co-Produced Comprehensive Transition Programme Designed Using Experience-Based Co-Design to Support First-Line Nurse Managers","CTP","Inclusion Criteria:\n\n* Clinical nurses with responsibility roles at Clínica Universidad de Navarra (CUN) but not yet formally appointed as supervisors.\n* First-Line Nurse Managers (FLNMs) with less than five years of managerial experience in the CUN.\n* FLNMs with more than five years of managerial experience acquired mainly in other institutions but recently appointed as first-line managers at the CUN.\n* Ability to understand and provide informed consent.\n\nExclusion Criteria:\n\n* Nurses with more than five years of continuous experience as FLNMs at the CUN.\n* Nurses in middle or executive management roles (e.g., area directors, chief nursing officers).\n* Clinical nurses without any responsibility or leadership role.\n* Inability or unwillingness to provide informed consent.",{"count":389,"type":23},22,[70],"This study will pilot a Comprehensive Transition Programme (CTP) to support nurses who move into first-line nurse manager (FLNM) roles at Clínica Universidad de Navarra. The transition to frontline management can be challenging and is linked to uncertainty, workload stress, and role ambiguity. The CTP was co-designed with clinical nurses, FLNMs, nursing directors and chief nursing officers using experience-based co-design methods so that its content fits the organisation's practice model and priorities.\n\nThe programme combines classroom training, online learning, mentorship, and structured reflective practice. Participants complete brief assessments before and after the programme. The primary focus is to see whether leadership practices improve; we will also examine feasibility and acceptability to inform future refinement.\n\nThis pilot uses a simple pre-post design with data collected at baseline and immediately after the programme. Findings will be used to optimise the CTP and to guide broader implementation in the health system.\n\n(Eligibility, outcomes, dates and intervention components are detailed in their specific sections of this record.)",[393],"Transition to First-Line Nurse Manager Role",[395,396,397,398,399,400],"Nursing leadership","First-line nurse managers","Nurse manager education","Mentorship","Leadership training","Co-Production","2025-09-22",{"date":403,"type":47},"2025-09-24",{"date":405,"type":23},"2025-10-03",{"date":407,"type":23},"2025-12-19",{"name":53,"class":54},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":417,"briefSummary":418,"conditions":419,"keywords":422,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":84},"100607104","effect-of-a-person-centred-care-intervention-for-families-providing-home-based-care-to-a-person-with-advanced-chronic-illness-a-pilot-randomised-controlled-trial-100607104","NCT07184216","Effect of a Person-Centred Care Intervention for Families Providing Home-Based Care to a Person With Advanced Chronic Illness: A Pilot Randomised Controlled Trial","HELP-F","Inclusion Criteria:\n\n1. Inclusion Criteria for the Person with Advanced Chronic Illness:\n\n   * Diagnosis of an advanced chronic disease, such as chronic heart failure (NYHA functional class IV), renal failure (stages 4-5), chronic obstructive pulmonary disease (COPD) (grades 4-5 on the MRC scale), or liver failure.\n   * Not currently receiving care from a specialized palliative care team.\n   * Habitual residence in their own home or that of a family member, without requiring permanent hospitalization.\n2. Inclusion Criteria for the Family Caregiving Unit:\n\n   * Actively providing care at home to an adult with advanced illness at the time of the study.\n   * A minimum of two months must have elapsed since the initiation of family caregiving for the person with advanced chronic illness at home.\n   * At least two or more adult family members of the person with advanced illness must participate in the study.\n3. Inclusion Criteria for Individual Caregivers\n\n   * Recognized as a caregiver by the person with advanced chronic illness.\n   * Aware of the advanced illness diagnosis of the care recipient.\n   * Aged 18 years or older.\n   * Able to communicate in Spanish.\n   * Having the physical and mental capacity to participate in the interview.\n   * Willing and able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Life expectancy of less than one year\n* Families experiencing an acute crisis situation (e.g., recent bereavement, severe family conflict).",{"count":284,"type":23},[70],"The goal of this clinical trial is to learn if a Person-Centred Care (PCC) intervention can improve the caregiving experience and wellbeing of families who provide home care for a loved one with advanced chronic illness. The main questions it aims to answer are:\n\n* Does the PCC intervention improve families' caregiving experience, preparedness for caregiving, and psychological wellbeing?\n* Is the PCC intervention feasible and acceptable for implementation in primary care settings?\n\nResearchers will compare families who receive the PCC intervention in addition to usual care to families who receive usual care alone.\n\nParticipants will:\n\n* Take part in an initial in-person consultation with a primary care nurse to share their family caregiving experience and co-create a personalized health plan.\n* Have monthly follow-up contacts with the same nurse over a 3-month period to update and adapt the plan.\n* Receive a copy of the updated plan after each contact to guide caregiving and support decision-making.",[420,421],"Chronic Illness","Caregivers",[423,424,425,426,427,428,429,430,431,432,433,434,435,436,437],"Person-centredness","RCT","Partnership","Health plan","Person-centred care","Person-centered care","Patient-centered care","Home care","In-home care","Home-based care","Community home care","Carers","Family caregivers","Informal caregivers","Care providers","2025-09-13",{"date":440,"type":47},"2025-09-19",{"date":442,"type":23},"2025-10-01",{"date":209,"type":23},{"name":53,"class":54},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":64,"sex":18,"minAge":65,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":84},"100605671","impact-of-satiating-compounds-and-hypocaloric-diet-on-weight-cardiometabolic-and-osteoarticular-health-in-obesity-100605671","NCT07165548","Impact of Satiating Compounds and Hypocaloric Diet on Weight, Cardiometabolic and Osteoarticular Health in Obesity","Evaluation of the Effect of Supplementation With Satiating Compounds Integrated Into a Hypocaloric Diet on Weight and Cardiometabolic and Osteoarticular Health in Overweight\u002FObese Subjects","COGLUBOCO","Inclusion Criteria:\n\n* Volunteers of both sexes between the ages of 18 and 65 years old.\n* Volunteers with grade II overweight or obesity (BMI: 27.0-39.9 kg\u002Fm2).\n* Physical examination and vital signs are normal or clinically irrelevant to the study.\n* Volunteers receiving pharmacological treatment may be included if the dosage has remained stable for at least three months prior to study initiation.\n* Individuals undergoing treatment for diabetes will be excluded.\n* Participants must be capable of understanding the study requirements, willing to provide written informed consent, and able to comply with all study procedures and timelines.\n* Body weight must have remained stable (±5%) during the three months preceding study initiation.\n\nExclusion Criteria:\n\n* Presence of significant functional or structural abnormalities of the digestive system, including but not limited to congenital malformations, angiodysplasia, active peptic ulcer disease, chronic inflammatory or malabsorption disorders, hiatal hernia, or chronic gastroesophageal reflux.\n* High alcohol consumption, defined as \\>14 units per week for women and \\>20 units per week for men.\n* Pregnancy or lactation at the time of screening.\n* History of surgical procedures resulting in permanent alterations of the digestive system (e.g., gastroduodenostomy) or joint replacement surgery (hip or knee).\n* Diagnosis of arthritis.\n* History of any liver disease, with the exception of non-alcoholic fatty liver disease.\n* Diagnosis of any type of cancer, current cancer treatment, or history of cancer treatment within the past five years.\n* Known allergy or hypersensitivity to any component of the investigational product or to any food that could interfere with study participation and follow-up.\n* Presence of cognitive and\u002For psychological impairment that could affect study compliance.\n* Anticipated poor adherence or, in the opinion of the investigator, inability to comply with study procedures.\n* Engagement in night-shift work.\n* Current use of dietary supplements that may interfere with study outcomes (e.g., nutraceuticals containing compounds with potential weight loss effects).\n* Ongoing treatment for weight loss or diabetes.","65 Years",{"count":455,"type":23},144,[70],"The main objective of this intervention study is to evaluate the effect of satiating protein and\u002For fiber bar consumption on weight loss and other osteoarticular and cardiometabolic parameters related to excess weight in subjects with overweight or obesity.\n\nTo achieve this objective, volunteers will be instructed to consume three bars per day as part of a hypocaloric diet, in accordance with healthy nutritional guidelines, over a 12-week period.\n\nThe main questions to answer are:\n\n* Does the regular consumption of these protein and\u002For fiber bars help to lose weight?\n* Does the regular consumption of these protein and\u002For fiber bars help to improve the osteoarticular health?\n* Does the regular consumption of these protein and\u002For fiber bars help to improve the cardiometabolic health?\n\nThe specific objectives are focused on evaluating the effects of the intervention on the following parameters:\n\n* Weight and body composition.\n* Knee joint range of motion.\n* Blood biomarkers related to collagen degradation and synthesis, associated with osteoarticular health.\n* Glycemic and lipid profiles, blood pressure, and biomarkers of kidney, liver, cardiovascular, and inflammatory health.\n* Changes in joint discomfort (improvement or worsening).\n* Adherence to the assigned intervention, including both dietary compliance and intake of the study-provided supplement.\n* Satiety-related variables assessed using a visual analog scale (VAS).\n* Urinary hydroxyproline and stool samples for metagenomic analysis.\n* Gastrointestinal health, mental health, quality of life, and physical activity level assessed through validated questionnaires.\n\nTarget sample size is 144 subjects and participants will be allocated in four different groups:\n\n* Group 1 (n=36): hypocaloric diet + protein and fiber supplement.\n* Group 2 (n=36): hypocaloric diet + protein and fiber supplement.\n* Group 3 (n=36): hypocaloric diet + fiber supplement.\n* Group 4 \"Placebo group\" (n=36): hypocaloric diet + placebo supplement. Participants will attend the nutritional intervention unit at weeks 1, 8, and 12. A follow-up phone call will be conducted at week 4.",[167,459],"Overweight",[461,462,463,464,465,167,466,467,468,469,470],"Nutritional intervention","Dietary supplement","Protein bar","Fiber bar","Hypocaloric Diet","Weight loss","Satiety","Cardiometabolic health","Osteoarticular health","Quality of life","2025-09-08",{"date":473,"type":47},"2025-09-10",{"date":475,"type":47},"2025-08-20",{"date":209,"type":23},{"name":53,"class":54},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":64,"sex":18,"minAge":65,"maxAge":189,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":488,"briefSummary":489,"conditions":490,"keywords":493,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":84},"100605664","effect-of-probiotic-intake-in-healthy-population-100605664","NCT07165457","Effect of Probiotic Intake in Healthy Population","Clinical Evaluation of a Probiotic in Healthy Population (PROBIO)","PROBIO","Inclusion Criteria:\n\n* Healthy men and women aged between 18 and 70 years.\n* Stable body weight (±5%) during the three months prior to study initiation.\n* Physical examination and vital signs within normal limits or clinically irrelevant for the study.\n* Subjects must be able to understand and willing to sign the informed consent form, and comply with all study procedures and requirements.\n* Ongoing pharmacological\u002Fhormonal treatment will be permitted provided it does not affect the parameters under investigation and the dosage has been stable for at least three months prior to study initiation.\n* Willingness to undergo all study procedures, including daily consumption of one probiotic capsule during the intervention.\n* Availability in terms of time and location to attend the two scheduled in-person clinical evaluation sessions.\n\nExclusion Criteria:\n\n* Volunteers undergoing pharmacological treatment with unstable dosing (less than 3 months prior to study initiation) will be excluded, particularly if treatments:\n* Affect gastrointestinal function.\n* Include chronically prescribed stomach protectants.\n* Subjects with significant functional or structural abnormalities of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.\n* Subjects who have undergone surgical procedures resulting in permanent alterations of the digestive system (e.g., gastroduodenostomy) or bariatric surgery.\n* Presence of systemic intestinal, hepatic, or renal diseases, such as uncontrolled thyroid disorders, cirrhosis, inflammatory bowel disease, untreated anemia, etc. (non-alcoholic fatty liver disease will not be excluded).\n* Alcohol consumption exceeding the sex-specific limits (\\>14 units\u002Fweek for women, \\>20 units\u002Fweek for men).\n* Pregnancy, lactation, or plans to become pregnant during the study period.\n* Use of nutritional supplements that may affect study outcomes (e.g., weight-loss supplements, newly initiated fiber supplements, probiotics, postbiotics, etc.).\n* Subjects with any type of cancer currently undergoing treatment, or with less than five years since cancer remission.\n* Known allergy to any component of the investigational product.\n* Presence of cognitive and\u002For psychological impairments.\n* Anticipated poor compliance or, in the investigator's opinion, difficulty adhering to study procedures.\n* Participation in any weight loss or body composition modification treatments.\n* Use of antibiotics within 15 days prior to the baseline visit.",{"count":487,"type":23},20,[70],"The main objective of this project is to evaluate the absence of adverse gastrointestinal effects following the consumption of a daily probiotic capsule during 15 days.\n\nThe secondary objective of this study is to verify the absence of any adverse effects other than gastrointestinal ones following the daily consumption of a probiotic during 15 days in a healthy population.\n\nSpecific objectives are:\n\n* To evaluate changes in gastrointestinal health through self-reported questionnaire.\n* To determine the adherence to probiotic consumption.\n* To analyse headache, tiredness\u002Ffatigue, muscle or joint pain, fever or low-grade fever, chills, allergic reactions, difficulty sleeping, dizziness and general discomfort by General Adverse Effects Questionnaire.\n\nTarget sample size is 20 subjects.\n\nParticipants will be allocated in one group (experimental group).\n\nParticipants will visit nutritional intervention unit at Clinical Investigation Day 1 (day 1) and at Clinical Investigation Day 2 (day 15).",[491,492],"Adverse Effects","Healthy",[494,495,201,496],"Probiotic","Supplement","Gastrointestinal tract","2025-09-02",{"date":473,"type":47},{"date":500,"type":23},"2025-09-04",{"date":502,"type":23},"2025-10-07",{"name":53,"class":54},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":24,"phases":513,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100595008","mri-guided-bladder-preservation-program-for-patients-with-muscle-invasive-bladder-cancer-100595008","NCT07026864","MRI-Guided Bladder Preservation Program For Patients With Muscle Invasive Bladder Cancer","Project #1: MRI-guided Bladder Cancer Preservation Program","Inclusion Criteria:\n\n1. Patients with T2-T3N0M0 unifocal bladder cancer of any histologic subtype except squamous cell carcinoma or adenocarcinoma (Janopaul-Naylor et al., 2021) treated the maximal TURBT and able to tolerate concurrent chemoradiotherapy. Selected patients with high risk of common iliac involvement (T4 disease and\u002For limited N+ disease and\u002For LVSI+ status) able to receive the following treatment may be included as well. Additional criteria include:\n2. Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;\n3. WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n\nExclusion Criteria:\n\n1. Prior radiation therapy to the target areas;\n2. Inability to undergo a MRI exam",{"count":512,"type":23},31,[70],"The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of bladder preservation as well as to decrease complications in patients with muscle invasive bladder cancer who wish to retain their bladders",[516],"Muscle Invasive Bladder Cancer (MIBC)",[518,519,520,521],"Muscle Invasive Bladder Cancer","Bladder Preservation","Radiation Therapy","MR-Guided Radiation Therapy","2025-08-22",{"date":524,"type":47},"2025-08-24",{"date":442,"type":23},{"date":527,"type":23},"2030-07-01",{"name":53,"class":54},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":24,"phases":537,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":4},"100603095","mri-guided-dose-intensification-program-locally-advanced-pancreatic-cancer-100603095","NCT07132060","MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Selection criteria includes patients with unresectable and borderline resectable and medically inoperable pancreatic cancer that will receive neoadjuvant chemotherapy followed by chemoirradiation.\n* No prior radiation therapy to the target areas;\n* Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including neoadjuvant chemotherapy followed by chemoirradiation.\n* WBC equal or greater than 3500 mm\\^3; platelet count equal or greater than 135000 mm\\^3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n\nExclusion Criteria:\n\n* Inability to undergo an MRI scan","80 Years",{"count":5,"type":23},[70],"The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer",[369],[541,542,543],"MRI-guided irradiation","Dose escalation","Ultrahypofractionation",{"date":545,"type":47},"2025-08-27",{"date":442,"type":23},{"date":548,"type":23},"2030-06-30",{"name":53,"class":54},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":535,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":559,"briefSummary":560,"conditions":561,"keywords":563,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":570,"leadSponsor":571,"locationsCount":4},"100603267","magnetic-resonance-imaging-mri-guided-rectal-cancer-preservation-program-100603267","NCT07134296","Magnetic Resonance Imaging (MRI)-Guided Rectal Cancer Preservation Program","MRI-guided Rectal Cancer Preservation Program","Inclusion Criteria:\n\n* Patients aged 18 or older with primary Stage II (T3-4, N0) or Stage III (any T, N1-2) biopsy-proven rectal cancer\n* No prior radiation therapy to the target areas;\n* ECOG 0-2 with medical status not contraindicating treatment with radical intent including TNT and TME (if required) and with basal laboratory values as follows:\n\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3\n  * Platelets ≥ 50,000 cells\u002Fmm3.\n  * Hemoglobin ≥ 8.0 g\u002Fdl.\n  * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\\u003C 4 x upper limit of normal.\n  * Total bilirubin \\\u003C 2 x upper normal mg\u002FdL.\n  * Alkaline phosphatase \\\u003C 4 x upper limit of normal.\n\nExclusion Criteria:\n\n* Patient unable to undergo an MRI examination",{"count":558,"type":23},32,[70],"The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of rectal preservation",[562],"Rectal Cancer",[564,565,566],"TNT","MRI-guided Irradiation","Rectal Preservation",{"date":568,"type":47},"2025-08-21",{"date":442,"type":23},{"date":548,"type":23},{"name":53,"class":54},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":579,"minAge":65,"maxAge":535,"enrollmentInfo":580,"targetDuration":4,"studyType":24,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":594,"leadSponsor":595,"locationsCount":4},"100603142","mri-guided-brachytherapy-and-salvage-sbrt-program-100603142","NCT07132671","MRI-guided Brachytherapy and Salvage SBRT Program","MRI-guided Brachytherapy + Salvage SBRT Program for Patients With Prostate Bed Relapses After Radical Prostatectomy","Patients with increasing PSA after RP and clinical evidence of PET PSMA\u002FCholine+ and RMN+ isolated prostatic bed relapse (IPBR) that is implantable via transperineal route . The IPBR should be visible on TRUS imaging to allow proper implant placement.\n\n1. Pathological confirmation is advised in all cases but it is not mandatory .\n2. Patients with any of the following were not considered eligible:\n\n   1. Distance \\\u003C 5mm from the edge of the IPBR to any of the defined OARs (UV anastomosis, rectal wall, bladder wall, external urinary sphincter)\n   2. Distant Metastases\n   3. Isolated nodal relapses\n   4. Prior Irradiation to the IPBR area\n   5. Multicentric IPBRs\n   6. Life expectancy of less than 5 years or inability to tolerate and comply with an HDR procedure\n3. No prior radiation therapy to the target areas;\n4. Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;\n5. WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n6. Ability to undergo MRI scanning.","MALE",{"count":581,"type":23},29,[70],"Brachytherapy followed by MRI-guided irradiation has the potential to improve treatment results in patients with local relapses after radical prostatectomy",[585],"Prostate Cancer (Post Prostatectomy)",[587,588,589,590],"Prostate Cancer","Prostate Bed Relapse","Brachytherapy","MR-Guided SBRT","2025-08-12",{"date":475,"type":47},{"date":442,"type":23},{"date":548,"type":23},{"name":53,"class":54},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":579,"minAge":65,"maxAge":603,"enrollmentInfo":604,"targetDuration":4,"studyType":24,"phases":605,"briefSummary":606,"conditions":607,"keywords":608,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":613,"leadSponsor":614,"locationsCount":4},"100603141","mri-guided-ultrahypofractionated-sbrt-prostate-program-100603141","NCT07132658","MRI-guided Ultrahypofractionated SBRT Prostate Program","PROJECT#2: MRI-guided Local SBRT Prostate Program","Optimal Inclusion Criteria\n\n* Patients with low to favorable intermediate-risk prostate cancer as per the NCCN stratification criteria .\n* No prior radiation therapy to the target areas\n* Expected patient survival \\>5 years\n* Patient able to undergo a MRI exam\n\nCautionary Inclusion Criteria\n\n* Suboptimal candidates for high-dose therapy such as elderly, frail patients or patients with large volume glands (i.e, \\>60cm3) or extensive TURP in the prior 6-12 months should be considered cautionary indications.\n* Patients with higher risk but low volume disease not candidates for ENI may be treated on an individual basis\n\nExclusion Criteria\n\n* Prior radiation therapy to the target areas\n* Expected patient survival below 5 years\n* Patient unable to undergo a MRI exam","85 Years",{"count":335,"type":23},[70],"The goal of this clinical trial is to learn if the use of MRI-guided asymmetric ultrahipofractionated irradiation (2 fractions with dose increase in the tumor areas and dose sparing in urethra, rectum and neurovascular bundles) produces similar results in terms of local control and complications to standard 5-fraction SBRT.",[587],[587,609,610],"NCCN Low Risk","NCCN Favorable Intermediate Risk",{"date":475,"type":47},{"date":442,"type":23},{"date":548,"type":23},{"name":53,"class":54},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":160,"minAge":65,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":4},"100601660","study-for-prevention-of-cervical-cancer-in-spain-100601660","NCT07113379","Study for Prevention of Cervical Cancer in Spain","REVIVE","Inclusion Criteria:\n\n* Female patients diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix.\n* Diagnosis established between 2019 and 2024.\n\nExclusion Criteria:\n\n* Patients aged below 18 years at diagnosis.\n* Diagnosis of other cervical cancer histologies (e.g., neuroendocrine tumors, sarcoma, lymphoma).\n* Patents with significant cognitive impairment precluding informed consent for data utilization, where applicable.\n* Patients with incomplete medical records relevant to the study variables.",{"count":139,"type":23},"The REVIVE study aims to analyze the current status of Human Papillomavirus (HPV) vaccination programs and cervical cancer screening strategies in Spain. Its objective is to gain a comprehensive understanding of the effectiveness of these preventive measures, as well as to identify the main barriers to access and the existing inequalities in care. The study will also examine the impact of misinformation on population engagement and on the overall equity of the prevention system.\n\nDespite significant advances in both vaccination and screening efforts, cervical cancer remains a major public health concern in Spain. In 2024 alone, 2,259 new cases were diagnosed, that incidence has remained relatively stable in recent years, even decades. Mortality rates have also shown little change, with over 600 deaths annually, totaling nearly 10,000 in the last 15 years.\n\nTo address this, the study plans to include approximately 200 patients diagnosed with cervical cancer in Spain between 2019 and 2024. It is a retrospective, observational, and non-interventional study. Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.",[625,626],"Cervical Cancer Screening","HPV Vaccination","2025-08-07",{"date":629,"type":47},"2025-08-08",{"date":631,"type":23},"2025-10",{"date":633,"type":23},"2026-10",{"name":53,"class":54},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":160,"minAge":65,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":4},"100597529","design-and-validation-of-plasma-proteins-and-cytokine-panels-to-identify-markers-associated-with-response-to-niraparib-as-maintenance-treatment-after-first-line-platinum-based-regimen-in-patients-with-advanced-ovarian-cancer-100597529","NCT07059676","Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer","LIBINI-1","Inclusion Criteria\n\n1. Signed informed consent and ability to comply with treatment and follow up.\n2. Patients ≥ 18 years old.\n3. ECOG 0-1\n4. Histologically confirmed diagnosis of FIGO stage III-IV high-grade serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.\n5. BRCA status according to local practice is known. It is encouraged to have BRCA testing in tumor.\n6. Homologous recombination status according to local practice is encouraged.\n7. Patients must meet the following front-line therapy requirements:\n\n   1. Patients must have received at least 4 cycles of platinum-based therapy\n   2. Patients must have non-evidence of disease or achieved a complete or partial response to platinum-based regimen Patient must meet all the required criteria for niraparib maintenance as single agent after first line platinum-based chemotherapy and receive niraparib therapy according to local prescribing information (see ANNEX 3).\n\nExclusion Criteria\n\n1. According to niraparib's local prescribing information (see ANNEX 3): Patients must not be pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 6 months after the last dose of study treatment. Women of childbearing potential must have a negative serum pregnancy test result within 72 hours prior to initiation of study treatment and have to use an effective contraceptive method along the participation in the study.\n2. Patients must not have a known hypersensitivity to the components of niraparib or the excipients.\n3. Patients must not have received prior treatment with a known PARP inhibitor.\n4. Patients must not have had any known, persistent (\\>4 weeks), ≥Grade 3 hematological toxicity or fatigue from prior cancer therapy.\n5. Patients must not have any known history of myelodysplastic syndrome (MDS) or a pretreatment cytogenetic testing result at risk for a diagnosis of MDS\u002Facute myeloid leukemia (AML).\n6. Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.",{"count":643,"type":23},120,"PARPi inhibitors have been incorporated into managing first-line advanced ovarian cancer with different approvals depending on homologous recombination (HR) status. Niraparib has received approval independent from HR status. Although the benefit is more remarkable in HR-deficient patients, there is no biomarker to predict sustained response to niraparib at the start of treatment helping the clinician to make decisions among the different treatment options.\n\nThe aim of the LIBINI-1 (Liquid biopsy for predicting niraparib benefit if 1st line) study is to identify predictive biomarkers of sustained response to niraparib using liquid biopsy with two different technologies:\n\n1. Proteomic and secretome analysis tools. The first part of the LIBINI-1 project is to create a platform for rapid screening and analysis by multiple detections of niraparib response-associated proteins in patients with advanced ovarian cancer.\n2. ctDNA analysis. The second part of the LIBINI-1 project is to correlate the baseline level of ctDNA and change in ctDNA at 4 and 12 weeks with the benefit to niraparib.",[646],"Advanced Ovarian Cancer","2025-07-01",{"date":649,"type":47},"2025-07-11",{"date":651,"type":23},"2025-07-25",{"date":653,"type":23},"2028-03-31",{"name":53,"class":54},""]